Figures & data
Figure 1 The two-part piezo-electric MiDD.
Notes: (A) The small handheld delivery system consists of an exchangeable upper section containing an ampoule reservoir prefilled with sterile ocular medication, which snaps into the lower ejection system containing system electronics and battery. (B) On push button activation, the MiDD releases a precisely calibrated and tightly collimated stream of aqueous ocular medication microdroplets. The system is designed to reliably administer any selected microdose, which can approach nanoliter scale. The MiDD demonstrably administers volumes down to 1.5 µL while maintaining a coefficient of variation below 15% (1.6±0.2 µL; CV=12.5%).Citation7
Abbreviation: MiDD, MicroDose dispenser.
Abbreviation: MiDD, MicroDose dispenser.
Table 1 Demographics and medical histories of study subjects
Figure 2 Mean diurnal IOP at baseline (unmedicated), Day 1, and Day 2 after 0.4 µg of 0.005% µRx-latanoprost morning microdosing and percentage change in mean diurnal IOP on Day 1 and Day 2 from the baseline.
Note: Data derived from the left/right eye average measurements for 29 evaluable subjects.
Figure 3 Mean diurnal IOP for average of left and right eyes after morning microdosing with 8 µL of 0.005% µRx-latanoprost (0.4 µg total dose).
Note: N=29 evaluable subjects.
Abbreviations: D, day; H, hour.
Abbreviations: D, day; H, hour.
Figure 4 Percent diurnal IOP reduction with 8 µL of 0.005% µRx-latanoprost (0.4 µg total dose).
Note: N=29 evaluable subjects.
